MX2019005144A - Tratamiento de cáncer de mama positivo para her2. - Google Patents
Tratamiento de cáncer de mama positivo para her2.Info
- Publication number
- MX2019005144A MX2019005144A MX2019005144A MX2019005144A MX2019005144A MX 2019005144 A MX2019005144 A MX 2019005144A MX 2019005144 A MX2019005144 A MX 2019005144A MX 2019005144 A MX2019005144 A MX 2019005144A MX 2019005144 A MX2019005144 A MX 2019005144A
- Authority
- MX
- Mexico
- Prior art keywords
- her2
- trastuzumab
- breast cancer
- treatment
- administration
- Prior art date
Links
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 title abstract 2
- 229960000575 trastuzumab Drugs 0.000 abstract 4
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 3
- 238000002512 chemotherapy Methods 0.000 abstract 3
- 229960002087 pertuzumab Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010048610 Cardiotoxicity Diseases 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 231100000259 cardiotoxicity Toxicity 0.000 abstract 1
- 230000007681 cardiovascular toxicity Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
Se proveen métodos para el tratamiento de cáncer de mama positivo para HER2 mediante administración neoadyuvante de pertuzumab y trastuzumab en combinación con quimioterapia a base de antraciclina. En particular, los métodos conciernen los pacientes de tratamiento con cáncer de mama positivo para HER2 de estadio temprano, inflamatorio o localmente avanzado mediante administración de neoadyuvantes de pertuzumab y trastuzumab después de quimioterapia a base de antraciclina, en donde la administración combinada de pertuzumab y trastuzumab aumenta la respuesta completa patológica (pCR) con respecto a la administración de trastuzumab como agente simple, sin aumento significativo de eventos adversos, tales como toxicidad cardíaca, con referencia a quimioterapia con base en antraciclina neoadyuvante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662417966P | 2016-11-04 | 2016-11-04 | |
PCT/US2017/059680 WO2018085513A1 (en) | 2016-11-04 | 2017-11-02 | Treatment of her2-positive breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019005144A true MX2019005144A (es) | 2019-10-14 |
Family
ID=61257088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019005144A MX2019005144A (es) | 2016-11-04 | 2017-11-02 | Tratamiento de cáncer de mama positivo para her2. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20180134803A1 (es) |
EP (1) | EP3534948A1 (es) |
JP (1) | JP2019532999A (es) |
KR (1) | KR20190075114A (es) |
CN (1) | CN110505880A (es) |
AU (1) | AU2017355432A1 (es) |
CA (1) | CA3040913A1 (es) |
IL (1) | IL266324A (es) |
MX (1) | MX2019005144A (es) |
TW (1) | TW201818940A (es) |
WO (1) | WO2018085513A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US10380152B2 (en) * | 2016-01-19 | 2019-08-13 | International Business Machines Corporation | Cognitive system comparison and recommendation engine |
EP3570884B1 (en) | 2017-01-17 | 2020-09-30 | Genentech, Inc. | Subcutaneous her2 antibody formulations |
CN117180422A (zh) * | 2017-03-02 | 2023-12-08 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
CN115003691A (zh) * | 2020-01-13 | 2022-09-02 | 西托戴恩股份有限公司 | 用于治疗ccr5阳性转移癌的ccr5结合剂 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
EP0474727B1 (en) | 1989-05-19 | 1997-07-23 | Genentech, Inc. | Her2 extracellular domain |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
PT1897890E (pt) | 1996-11-27 | 2010-02-23 | Genentech Inc | Purificação por afinidade de um polipéptido numa matriz de proteína a |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
CA2324494A1 (en) | 1998-03-27 | 1999-09-30 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
ES2198913T5 (es) | 1998-05-06 | 2013-11-18 | Genentech, Inc. | Purificación de proteínas mediante cromatografía de intercambio iónico |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
ATE415979T1 (de) | 1999-05-14 | 2008-12-15 | Genentech Inc | Behandlung mit anti-erbb2 antikörpern |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
DK1189634T3 (da) | 1999-06-25 | 2007-06-25 | Genentech Inc | Behandling af prostatacancer med anti-ErbB2-antistoffer |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
ES2330301T3 (es) | 1999-08-27 | 2009-12-09 | Genentech, Inc. | Dosificaciones para tratamiento con anticuerpos anti-erbb2. |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
NZ522444A (en) | 2000-05-19 | 2004-09-24 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
US6695940B2 (en) | 2001-04-05 | 2004-02-24 | Alan D. Devoe | Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells |
US20040048525A1 (en) | 2002-01-28 | 2004-03-11 | Sagucio Esteban N. | Watercycle for wet rider |
CA2481515C (en) | 2002-04-10 | 2013-10-01 | Genentech, Inc. | Anti-her2 antibody variants |
BR0312534A (pt) | 2002-07-15 | 2007-03-13 | Genentech Inc | método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura |
US6982719B2 (en) | 2002-07-15 | 2006-01-03 | Sun Microsystems, Inc. | Switching sample buffer context in response to sample requests for real-time sample filtering and video generation |
JP2006516117A (ja) | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ErbB2抗体を用いた非悪性疾病または疾患の治療 |
PT3095793T (pt) | 2003-07-28 | 2020-05-04 | Genentech Inc | Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a |
JP4969440B2 (ja) | 2004-04-08 | 2012-07-04 | デビッド, ビー. エイガス, | 疼痛治療のためのErbBアンタゴニスト |
US7195440B2 (en) | 2004-05-27 | 2007-03-27 | Lambert Charles F | Agricultural silo auger system apparatus and method |
KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
ZA200701234B (en) | 2004-07-22 | 2008-12-31 | Genentech Inc | HER2 antibody composition |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006063042A2 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
EP2399605A1 (en) | 2005-02-23 | 2011-12-28 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
EP1971367A4 (en) | 2005-12-05 | 2010-04-07 | Trinity Biosystems Inc | METHOD AND COMPOSITIONS FOR THE NEEDLESS DELIVERY OF BINDING PARTNERS |
WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
BRPI0812682A2 (pt) * | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
EP2575880B1 (en) * | 2010-05-27 | 2019-01-16 | Genmab A/S | Monoclonal antibodies against her2 epitope |
RU2013131232A (ru) * | 2010-12-09 | 2015-01-20 | Дженентек, Инк. | Лечение her2-позитивного рака при помощи паклитаксела и трастузумаба-mсc-dm1 |
PL2766040T3 (pl) * | 2011-10-14 | 2019-11-29 | Hoffmann La Roche | Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi |
SG11201509508YA (en) * | 2013-06-19 | 2015-12-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof |
-
2017
- 2017-11-02 TW TW106137942A patent/TW201818940A/zh unknown
- 2017-11-02 WO PCT/US2017/059680 patent/WO2018085513A1/en active Application Filing
- 2017-11-02 CN CN201780067414.8A patent/CN110505880A/zh active Pending
- 2017-11-02 AU AU2017355432A patent/AU2017355432A1/en not_active Abandoned
- 2017-11-02 KR KR1020197015632A patent/KR20190075114A/ko not_active Application Discontinuation
- 2017-11-02 MX MX2019005144A patent/MX2019005144A/es unknown
- 2017-11-02 CA CA3040913A patent/CA3040913A1/en not_active Abandoned
- 2017-11-02 US US15/801,937 patent/US20180134803A1/en not_active Abandoned
- 2017-11-02 JP JP2019523721A patent/JP2019532999A/ja active Pending
- 2017-11-02 EP EP17844587.0A patent/EP3534948A1/en not_active Withdrawn
-
2019
- 2019-04-29 IL IL266324A patent/IL266324A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20180134803A1 (en) | 2018-05-17 |
EP3534948A1 (en) | 2019-09-11 |
WO2018085513A1 (en) | 2018-05-11 |
AU2017355432A1 (en) | 2019-05-16 |
CA3040913A1 (en) | 2018-05-11 |
CN110505880A (zh) | 2019-11-26 |
JP2019532999A (ja) | 2019-11-14 |
KR20190075114A (ko) | 2019-06-28 |
TW201818940A (zh) | 2018-06-01 |
IL266324A (en) | 2019-06-30 |
WO2018085513A9 (en) | 2018-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019005144A (es) | Tratamiento de cáncer de mama positivo para her2. | |
PH12020500240A1 (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
WO2019094692A3 (en) | Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment | |
PH12018500714A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
MX2021014137A (es) | Pertuzumab para usarse en el tratamiento de cancer de mama her2 positivo. | |
AU2015249633A8 (en) | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab | |
WO2016172494A3 (en) | Combination of immunotherapy with local chemotherapy for the treatment of malignancies | |
PH12015501744A1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
BR112017023269A2 (pt) | métodos para tratamento de câncer | |
MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
MX2017013074A (es) | Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer. | |
MX2019006331A (es) | Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos. | |
MX2018005830A (es) | Composiciones y metodos para tratar enfermedades autoinmunes y canceres. | |
WO2017049038A3 (en) | Anti-cd115 antibodies | |
WO2014169221A3 (en) | Cancer therapy | |
MX2020005640A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. | |
EP3723772A4 (en) | COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR THE TREATMENT OF CANCER AND METABOLIC INTERVENTION THERAPY | |
WO2016191675A3 (en) | Antibodies against glypican-3 and their uses in cancer diagnosis and treatment | |
EP3314250A4 (en) | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells | |
PH12021550376A1 (en) | Combination therapy | |
MX2019000677A (es) | Células miméticas de células b. | |
WO2016196373A3 (en) | Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
BR112019025164A2 (pt) | Esquema de dosagem para tesetaxel e capecitabina |